Trump Says Anthropic No Longer Seen as National Security Threat 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 8:30 AM Pacific Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20209. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
